Nutritional Intervention for Age-related Muscular Function and Strength Losses-Study 2

Overview

Men and women lose muscle mass and strength with age. Loss of muscle mass and strength is accompanied by a loss of muscle function which can lead to diminished quality of life and more importantly can lead to serious fall requiring medical treatment. The investigators hypothesize that the combined supplements of Calcium-HMB and Vitamin D will lead to decreased falls and to improved quality of life (QOL) for older adults. The investigators further hypothesize that the addition of a modest exercise regimen to these supplements will enhance the synergistic effects of both Calcium-HMB and Vitamin D. Subjects will consume the dietary supplement 2 times per day for 12 months. Tests will consist of the following: a) strength of subjects' legs and elbow by Isokinetic Dynamometer; b) body composition; c) hand-grip strength by hand-grip dynamometer; d) functional mobility, balance and agility (Get-Up and Get-Up-and-Go tests); e) filling out questionnaires; and g) having blood drawn for biochemical measurements. Testing will be performed at the baseline (0 months) and at 3, 6, 9, and 12 months.

Full Title of Study: “Year-long Double Blind Study on the Efficacy of a Combination of Beta-hydroxy-beta-methylbutyrate and Vitamin D With and Without Exercise on Muscular Strength and Functionality in Older Adults.”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Factorial Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: February 4, 2019

Interventions

  • Dietary Supplement: Placebo
    • A Placebo comparator
  • Drug: HMB plus Vitamin D
    • Active comparator of HMB (3 g/d) plus Vitamin D (2,000 IU/d)
  • Behavioral: Non-Exercise
    • This group will not participate in 3 times per week strength training
  • Behavioral: Exercise
    • This group will participate in a supervised 3 times per week strength training program

Arms, Groups and Cohorts

  • Placebo Comparator: Placebo Exercise
    • Placebo supplementation group with 3 days per week of exercise
  • Placebo Comparator: Placebo Non-exercise
    • Placebo supplementation group without exercise
  • Active Comparator: HMB plus Vitamin D Exercise
    • HMB plus Vitamin D supplementation group with 3 days per week of exercise
  • Active Comparator: HMB plus Vitamin D Non-exercise
    • HMB plus Vitamin D supplementation group without exercise

Clinical Trial Outcome Measures

Primary Measures

  • Muscular strength
    • Time Frame: 12 Months
    • Leg and elbow strength will be tested by Isokinetic dynamometer and Handgrip strength will be tested using a hand-grip dynamometer.

Secondary Measures

  • Functionality
    • Time Frame: 12 months
    • The Get-Up and Get-Up-and-Go tests will be used as a measure of functionality.

Participating in This Clinical Trial

Inclusion Criteria

  • Male and female subjects will be enrolled into the study. – Age > 60 years. – Free of liver and kidney diseases, and with no evidence of uncontrolled hypertension. – Does not have a chronic disease that affects calcium or bone metabolism (i.e., asthma with chronic use of high dose steroids, inflammatory bowel disease, Crohn's disease, primary hyperparathyroidism, seizure disorder with use of phenobarbital, etc.). – Not classified as morbidly obese (body mass index (BMI) >40 kg/m2). – Six weeks since major surgery (three weeks since minor surgery). – Willing to consume one of the nutritional supplements for the study period. – Individuals diagnosed with osteoporosis, or bone density > 2.0 standard deviations below the mean, will not be enrolled in the study. – No other serious medical illness. – Serum 25OH-vitD3 >15 ng/ml. – Willing to participate in 3-day-a-week monitored strength-training program. – Physician has placed no restriction on physical exercise. Exclusion Criteria:

  • Age < 60 years. – Evidence of liver and kidney diseases, uncontrolled hypertension, or Type I diabetes mellitus requiring insulin for glucose control. – Presence of a chronic disease that affects calcium or bone metabolism (i.e., asthma with chronic use of high dose steroids, inflammatory bowel disease, Crohn's disease, primary hyperparathyroidism, seizure disorder with use of phenobarbital, etc.). – Classified as morbidly obese (body mass index (BMI) >40 kg/m2). – Less than six weeks since major surgery or three weeks since minor surgery. – Not willing to consume one of the nutritional supplements for the study period. – Individuals diagnosed with osteoporosis, or a bone density > 2.0 standard deviations below the mean, will not be enrolled in the study. – Other serious medical illness, which the subject's doctor or medical review team has decided affects the subject's ability to participate in the study. – History of blood clots and/or the use of blood thinning medications – Subjects on high dose vitamin D therapies (i.e. 50,000 IU vitamin D). – Subjects with serum 25OH-vitD3 <10 ng/ml will be considered deficient and will be referred to their physician for treatment. – Subjects with serum 25OH-vitD3 >30 ng/ml may not respond to the intervention as expected and will also be excluded from the study. – Not able or willing to participate in 3-day-a-week monitored strength-training program. – Physician has placed a restriction on physical exercise.

Gender Eligibility: All

Minimum Age: 60 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Metabolic Technologies Inc.
  • Collaborator
    • Iowa State University
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • John A Rathmacher, PhD, Principal Investigator, Metabolic Technologies Inc.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.